Mental Health Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dementia
In 2009 Exonhit Aims to ask for Market Clearance in Europe for a Blood Diagnostic Test for Alzheimer's Disease
June 18th, 2007
ExonHit Therapeutics, a drug and diagnostic discovery company, today announces that, following additional scientific findings to those published in March 2007, it will ask for certification in Europe, and for market clearance in the USA, as early as 2009 for a multi-gene expression test assisted by an algorithm to produce a score that determines whether the patient is deemed with Alzheimer's disease (AD). Certification of a diagnostic test requires proving that the test can achieve what it has been designed to achieve. The certification program defined by ExonHit aims at proving that the test can differentiate Alzheimer's disease from other pathologies such as...
Source: Mental Health Weekly Digest (2007-06-18)
|
